Cargando…
A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification
Variceal hemorrhage may cause high rebleeding and mortality rates. Preventing the first episode of variceal bleeding is mandatory in patients with high-risk esophageal varices (EV). This study aimed to identify factors that predict the recurrence of EV after endoscopic treatment (ET), and to develop...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762126/ https://www.ncbi.nlm.nih.gov/pubmed/31557230 http://dx.doi.org/10.1371/journal.pone.0223153 |
_version_ | 1783454153018703872 |
---|---|
author | Ishikawa, Tsuyoshi Sasaki, Ryo Nishimura, Tatsuro Aibe, Yuki Saeki, Issei Iwamoto, Takuya Hidaka, Isao Takami, Taro Sakaida, Isao |
author_facet | Ishikawa, Tsuyoshi Sasaki, Ryo Nishimura, Tatsuro Aibe, Yuki Saeki, Issei Iwamoto, Takuya Hidaka, Isao Takami, Taro Sakaida, Isao |
author_sort | Ishikawa, Tsuyoshi |
collection | PubMed |
description | Variceal hemorrhage may cause high rebleeding and mortality rates. Preventing the first episode of variceal bleeding is mandatory in patients with high-risk esophageal varices (EV). This study aimed to identify factors that predict the recurrence of EV after endoscopic treatment (ET), and to develop a reasonable therapeutic strategy for EV in cirrhosis. From January 2012 to December 2014, 45 patients with cirrhosis and high-risk EV underwent ET, including sclerotherapy and/or ligation. Statistical analyses identified factors associated with the recurrence of EV after ET, and the Kaplan-Meier method determined the cumulative variceal recurrence rates. The 1-, 2-, and 3-year cumulative posttreatment recurrence rates for EV were 13.3%, 29.5%, and 32.2%, respectively. No significant differences were evident between the patients with and without variceal recurrences at 1-year posttreatment. The multivariate regression analyses identified a history of partial splenic embolization (PSE) and the pretreatment Child-Pugh classification as independent predictors of variceal recurrences at 2 years (p < 0.05) and 3 years (p < 0.05) posttreatment. While EV did not recur after ET and splenic artery embolization in cases with Child-Pugh class A, the overall posttreatment variceal recurrence rates were 0% and 66.7% when PSE was performed before and after ET, respectively, in those with Child-Pugh class B or C. Splenic artery embolization significantly reduced the hepatic venous pressure gradient and markedly lowered the Child-Pugh score in 15 patients. Adjunctive PSE and pretreatment Child-Pugh class A could be independently associated with reduced cumulative recurrence rates of EV post-ET. From the perspectives of portal hemodynamics and hepatic function, splenic artery embolization before or after ET could prevent posttreatment variceal recurrence in patients with Child-Pugh class A, and PSE before ET could achieve the long-term eradication of EV following ET in those with Child-Pugh class B or C. |
format | Online Article Text |
id | pubmed-6762126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-67621262019-10-12 A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification Ishikawa, Tsuyoshi Sasaki, Ryo Nishimura, Tatsuro Aibe, Yuki Saeki, Issei Iwamoto, Takuya Hidaka, Isao Takami, Taro Sakaida, Isao PLoS One Research Article Variceal hemorrhage may cause high rebleeding and mortality rates. Preventing the first episode of variceal bleeding is mandatory in patients with high-risk esophageal varices (EV). This study aimed to identify factors that predict the recurrence of EV after endoscopic treatment (ET), and to develop a reasonable therapeutic strategy for EV in cirrhosis. From January 2012 to December 2014, 45 patients with cirrhosis and high-risk EV underwent ET, including sclerotherapy and/or ligation. Statistical analyses identified factors associated with the recurrence of EV after ET, and the Kaplan-Meier method determined the cumulative variceal recurrence rates. The 1-, 2-, and 3-year cumulative posttreatment recurrence rates for EV were 13.3%, 29.5%, and 32.2%, respectively. No significant differences were evident between the patients with and without variceal recurrences at 1-year posttreatment. The multivariate regression analyses identified a history of partial splenic embolization (PSE) and the pretreatment Child-Pugh classification as independent predictors of variceal recurrences at 2 years (p < 0.05) and 3 years (p < 0.05) posttreatment. While EV did not recur after ET and splenic artery embolization in cases with Child-Pugh class A, the overall posttreatment variceal recurrence rates were 0% and 66.7% when PSE was performed before and after ET, respectively, in those with Child-Pugh class B or C. Splenic artery embolization significantly reduced the hepatic venous pressure gradient and markedly lowered the Child-Pugh score in 15 patients. Adjunctive PSE and pretreatment Child-Pugh class A could be independently associated with reduced cumulative recurrence rates of EV post-ET. From the perspectives of portal hemodynamics and hepatic function, splenic artery embolization before or after ET could prevent posttreatment variceal recurrence in patients with Child-Pugh class A, and PSE before ET could achieve the long-term eradication of EV following ET in those with Child-Pugh class B or C. Public Library of Science 2019-09-26 /pmc/articles/PMC6762126/ /pubmed/31557230 http://dx.doi.org/10.1371/journal.pone.0223153 Text en © 2019 Ishikawa et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ishikawa, Tsuyoshi Sasaki, Ryo Nishimura, Tatsuro Aibe, Yuki Saeki, Issei Iwamoto, Takuya Hidaka, Isao Takami, Taro Sakaida, Isao A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification |
title | A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification |
title_full | A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification |
title_fullStr | A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification |
title_full_unstemmed | A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification |
title_short | A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification |
title_sort | novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the child-pugh classification |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762126/ https://www.ncbi.nlm.nih.gov/pubmed/31557230 http://dx.doi.org/10.1371/journal.pone.0223153 |
work_keys_str_mv | AT ishikawatsuyoshi anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT sasakiryo anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT nishimuratatsuro anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT aibeyuki anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT saekiissei anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT iwamototakuya anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT hidakaisao anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT takamitaro anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT sakaidaisao anoveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT ishikawatsuyoshi noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT sasakiryo noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT nishimuratatsuro noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT aibeyuki noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT saekiissei noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT iwamototakuya noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT hidakaisao noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT takamitaro noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification AT sakaidaisao noveltherapeuticstrategyforesophagealvaricesusingendoscopictreatmentcombinedwithsplenicarteryembolizationaccordingtothechildpughclassification |